Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 3/20 | 0.57 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.57 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.57 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9890671 | 0.87 | PTGDR2 (0.50) | PTGER1PTGER4PTGER3PTGER2KDM4E | |
| SCHEMBL9890666 | 0.87 | PTGDR2 (0.50) | PTGER1PTGER4PTGER3PTGER2PTGS2 | |
| SCHEMBL9890683 | 0.87 | PTGS2 (0.52) | PTGER1PTGER4PTGER3PTGER2PTGS2 | |
| SCHEMBL2392257 | 0.86 | ICMT (0.54) | PTGER1PTGER4PTGER3PTGER2DCLRE1B | |
| SCHEMBL9890679 | 0.83 | KDM4E (0.49) | PTGER1PTGER4PTGER3PTGER2KDM4E | |
| SCHEMBL538512 | 0.82 | KMT2A (0.60) | PTGER1PTGER4PTGER3PTGER2PTGS2 | |
| SCHEMBL9890677 | 0.82 | PTGS2 (0.47) | PTGER2PTGS2KDM4ESMN1; SMN2PTGDR2 | |
| SCHEMBL9890680 | 0.82 | SRC (0.47) | PTGER2PTGS2KDM4ESMN1; SMN2PTGDR2 | |
| SCHEMBL9890674 | 0.82 | SUCNR1 (0.46) | KDM4ESMN1; SMN2PTGDR2TBXA2RPTGDR | |
| SCHEMBL2393439 | 0.82 | SMN1; SMN2 (0.46) | PTGER1PTGER4PTGER3PTGER2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2374790-A1 | BIPHENYLACETAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | PTGER1 1182/4885PTGER4 1681/4885PTGER3 1172/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | PTGER1 1182/4885PTGER4 1681/4885PTGER3 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.